NEURACAP
Sector OutlookPublished · 22 pages · Free to read

Outpatient and Specialty Care Services Sector Outlook — September 2026

A September 2026 sector outlook on Outpatient and Specialty Care Services, covering the public comparable universe, valuation drivers, precedent transactions and strategic implications for owners, operators and boards assessing business model and operating performance.

For information only. Not an appraisal or a fairness opinion.

What moved since: Outpatient and Specialty Care Services M&A update, 14–28 September 2026

Key figures

Premium-tier valuation
13.3x
EV/EBITDA (CY2027E), premium tier
Discount-tier valuation
5.9x
EV/EBITDA (CY2027E), discount tier
Facility-network share
77%
Share of approved universe
Sector median multiple
8.7x
EV/EBITDA (CY2027E), full rated set

Read the report

NeuraCap

HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › OUTPATIENT AND SPECIALTY CARE SERVICES

Outpatient and Specialty Care: Value and Quality Move Together

The report shows how operating profiles, business models and buyer priorities separate value across the sector.

September 2026 · Prepared by NeuraCap AI · Confidential

Market data as of 2026-09-28 · primary valuation basis EV / EBITDA (CY2027E)

Outpatient and Specialty Care Services Coverage | September 2026 | Confidential | Not investment advice

1

1 / 22

Executive summary

Outpatient and specialty care does not price as one operating model. Hospital-affiliated facility networks form 77% of the approved universe, while adjacent models make up 23%, and valuation separates on operating profile rather than segment alone. The premium end trades at 13.3x versus 5.9x at the discount end, with the widest gap sitting between names that clear both growth and margin bars (14.7x) and those that clear neither (6.4x). The report sets out where that premium concentrates and the operating questions it raises for owners, operators and boards.

Key findings

  • Facility networks are 77% of the set; adjacent models make up 23%
  • Premium-tier valuation reaches 13.3x versus 5.9x at the discount end
  • Faster-growing names trade at 9.9x versus 8.0x for slower ones
  • Clearing both growth and margin bars marks the top: 14.7x vs 6.4x

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01

    HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › OUTPATIENT AND SPECIALTY CARE SERVICES

    The cover page introduces the sector outlook and its scope within Health Care and Health Care Equipment and Services.

    This report examines the Outpatient and Specialty Care Services sector as of September 2026, using EV/EBITDA (CY2027E) as the primary valuation lens. We designed it so the bottom line stands on its own for any reader who reads no further.

    Everything on this page

    HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › OUTPATIENT AND SPECIALTY CARE SERVICES Outpatient and Specialty Care: Value and Quality Move Together The report shows how operating profiles, business models and buyer priorities separate value across the sector. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / EBITDA (CY2027E) Outpatient and Specialty Care Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    CONTENTS

    What This Report Covers

    The contents page lists the report's five sections plus the appendix.

    We front-load the bottom line so a reader who stops after section one still leaves with the full story. The sections that follow build the landscape, the valuation picture, the deal record and the strategic implications behind that headline.

    Everything on this page

    CONTENTS What This Report Covers 01 The Bottom Line The Sector Rewards a Narrow Mix of Growth, Profitability and Durable Care Economics 02 The Landscape Business Model Matters Before Company-Level Performance Enters the Comparison 03 Valuation & Situations Forward Earnings Separate the Premium End from the Discount End 04 Precedent Transactions Buyers Have Paid Across Care Delivery, Specialty Networks and Occupational Health 05 Strategic Implications Value Strengthens When Growth Converts into Durable Earnings 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Outpatient and Specialty Care Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2

  3. 03
    01 · THE BOTTOM LINE

    Outpatient and Specialty Care Contains a Scaled Hospital-Affiliated Core and Distinct Adjacent Models

    This page summarizes the sector's core finding: a scaled hospital-affiliated core alongside distinct adjacent models, with valuation tied to growth and margin.

    Hospital-affiliated facility networks make up 77% of the approved set, with adjacent models at 23%, so site of service and physician alignment sit at the center of the value conversation. The premium end of the peer set trades at 13.3x versus 5.9x at the discount end, a gap that already credits forecast growth. Among the rated names, faster-growing companies sit at 9.9x versus 8.0x for the slower group, and the names clearing both growth and margin bars reach 14.7x against 6.4x for those clearing neither. That spread is why we treat business model and operating profile as the starting point for any valuation discussion here.

    Everything on this page

    01 · THE BOTTOM LINE Outpatient and Specialty Care Contains a Scaled Hospital-Affiliated Core and Distinct Adjacent Models The full story on one page · figures on EV / EBITDA (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (12 of 13 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Qualitative characterisations are NeuraCap views. Outpatient and Specialty Care Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 The Sector’s Center of Gravity Sits in Facility Networks Hospital-affiliated outpatient and surgical facility networks represent 77% of the set, while adjacent models represent 23%. That mix puts site of service, case mix acuity and physician alignment at the center of the value discussion. 2 The Premium End Carries a Wide Valuation Lead The premium end sits at 13.3x versus 5.9x for the discount end. With a forward EV / EBITDA lens, that gap already credits forecast growth and points to differing market views on durability. 3 Faster Growth Is Associated with Higher Pricing Among the 12 names with a forward EV / EBITDA estimate, the six at or above 6% growth sit at 9.9x versus 8.0x for the six below. The operating test is whether that pace comes with credible same-store visit growth, de novo ramp and payer mix. 4 Clearing Both Operating Bars Marks Out the Top of the Range Among the 12 names with a forward EV / EBITDA estimate, the two clearing both growth and margin bars sit at 14.7x, while the two clearing neither sit at 6.4x. The contrast is consistent with buyers and public investors distinguishing profitable expansion from volume alone. 8.7x Sector median EV/EBITDA CY2027E consensus · 12 rated of 13 companies 13.3x Premium end EV/EBITDA vs 5.9x at the discount end top quartile (n=3) against bottom quartile (n=3) on EV/EBITDA — the spread the report explains 19 Transactions with disclosed terms 56 recorded in this tier · 3 told as case studies, the full list in the appendix

  4. 04
    SECTION 02

    02

    This divider introduces the section on business models across the sector.

    Before comparing individual companies, we need to separate the sector's distinct business models. Facility networks and adjacent models carry different earnings, payment and growth profiles.

    Everything on this page

    SECTION 02 02 THE LANDSCAPE Business Model Matters Before Company-Level Performance Enters the Comparison Facility networks and adjacent models carry different earnings, payment and growth profiles. 02 of 06 Outpatient and Specialty Care Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4

  5. 05
    02 · MARKET MAP

    Facility Networks Hold the Sector’s Center While Adjacent Models Broaden the Opportunity

    This page maps the approved companies by business segment and shows median valuation for each group.

    We group the approved universe by business segment to show where the sector's scale actually sits. Facility networks anchor the center of the market, while adjacent models extend the opportunity into different payment and growth profiles. Segment context matters here because it explains why company-level comparisons need to control for business model before they mean anything.

    Everything on this page

    02 · MARKET MAP Facility Networks Hold the Sector’s Center While Adjacent Models Broaden the Opportunity 13 approved companies grouped by business segment · median EV / EBITDA (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Outpatient and Specialty Care Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 HOSPITAL-AFFILIATED OUTPATIENT AND SURGICAL FACILITY NETWORKS 10 cos median 9.1x HCA Healthcare (HCA) Community Health (CYH) Surgery Partners (SGRY) Concentra Group (CON) Option Care Health (OPCH) Astrana Health (ASTH) Ardent Health (ARDT) U.S. Physical (USPH) Innovage Holding (INNV) The Joint (JYNT) This group represents 77% of the set and brings site-of-service economics, physician syndication and local referral density into focus. ADJACENT MODELS 3 cos median 7.0x National Vision (EYE) Alignment (ALHC) PROCEPT (PRCT) This group represents 23% of the set and adds distinct payment models, technology exposure and care formats.

  6. 06
    02 · LANDSCAPE

    Outpatient and Specialty Care: Two Models with Two Different Mixes of Growth and Margin

    This page compares the two dominant segments on their distinct growth and margin mixes.

    Facility networks and adjacent models are not interchangeable: they carry different mixes of growth and margin, and the approved universe splits 77% to 23% between them. We lay out what each model does and why it matters so the valuation pages that follow can be read in context. Understanding this mix is the foundation for reading the multiples in the next section.

    Everything on this page

    02 · LANDSCAPE Outpatient and Specialty Care: Two Models with Two Different Mixes of Growth and Margin Segment view of the approved universe · EV / EBITDA (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Outpatient and Specialty Care Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/EBITDA Names to know What they do — and why it matters Hospital-affiliated outpatient and surgical facility networks 10 77% 9.1x HCA Healthcare, Inc. (HCA) · Community Health Systems, Inc. (CYH) · +8 more Scale meets local care delivery. These networks combine facilities, clinicians and referral channels. Value depends on case mix acuity, block time utilization, payer contracts and the economics retained after physician interests. Adjacent models 3 23% 7.0x National Vision Holdings, Inc. (EYE) · Alignment Healthcare, Inc. (ALHC) · +1 more Different economics widen the frame. These businesses span risk-bearing care and procedure technology. Their revenue quality, margin maturity and capital needs differ from facility-led operators.

  7. 07
    SECTION 03

    03

    This divider introduces the section on public market valuation and what separates the premium end from the discount end.

    Forward earnings separate the premium end of this sector from the discount end. The range we're about to walk through reflects different combinations of growth, profitability and operating durability.

    Everything on this page

    SECTION 03 03 VALUATION & SITUATIONS Forward Earnings Separate the Premium End from the Discount End The range reflects different combinations of growth, profitability and operating durability. 03 of 06 Outpatient and Specialty Care Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7

  8. 08
    03 · PUBLIC MARKET VALUATION

    The Premium End Holds a Clear Lead, but Its Operating Profiles Differ

    This page ranks the rated companies by EV/EBITDA (CY2027E) against a sector median of 8.7x.

    We sort the full rated set by forward EV/EBITDA and mark the sector median at 8.7x. The premium end holds a clear lead over the rest of the set, but the operating profiles behind those multiples differ meaningfully. That gap is the starting point for the driver analysis on the following pages.

    Everything on this page

    03 · PUBLIC MARKET VALUATION The Premium End Holds a Clear Lead, but Its Operating Profiles Differ EV / EBITDA (CY2027E) · all 12 rated companies, sorted descending · sector median 8.7x · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (12 of 13 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / EBITDA (CY2027E) basis. Panel commentary is a NeuraCap view. Outpatient and Specialty Care Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 13.3x CORE · median 8.7x DISCOUNT · median 5.9x Sector median 8.7x WHAT SEPARATES THE TWO ENDS The valuation gap is clear. The premium end sits at 13.3x, while the discount end sits at 5.9x. The spread is observed across a small set with different care models and operating profiles. The premium profiles differ. The premium end includes balanced and margin-led profiles. That mix suggests investors are considering durability alongside the headline rate of growth. Forward pricing tests durability. A forward multiple already gives credit for forecast performance. Holding a premium on that basis is associated with confidence that earnings can persist.

  9. 09
    03 · VALUATION DRIVERS

    Profitability Separates the Two Ends: Names Above the 11% Margin Line Carry 10.9x Against 8.2x Below It

    This page shows that names above an 11% EBITDA margin line carry a higher median multiple than names below it.

    Splitting the rated set at the 11% margin line shows the higher-margin cohort at 10.9x against 8.2x for the lower-margin cohort. We read this as an association between profitability and how the market prices these names, not a claim that margin alone causes the premium. It's a clear enough gap that margin profile belongs in any valuation conversation about this sector.

    Everything on this page

    03 · VALUATION DRIVERS Profitability Separates the Two Ends: Names Above the 11% Margin Line Carry 10.9x Against 8.2x Below It Median EV / EBITDA (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=6; slower n=6; higher-margin n=6; lower-margin n=6). Driver readings are NeuraCap views on the supplied data — association, not causation. Outpatient and Specialty Care Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 EV/EBITDA, median per cohort · growth split at 6% · EBITDA-margin split at 11% The Growth Split Carries a Visible Valuation Difference Among the 12 names with a forward EV / EBITDA estimate, the six at or above 6% growth sit at 9.9x versus 8.0x for the six below. Revenue Quality Gives Growth Its Commercial Meaning Same-store visit growth, net revenue per case and payer mix distinguish repeatable operating progress from growth that depends on acquisitions or a still-ramping site base. Physician Economics Shape the Earnings Available to Owners For syndicated facilities, reported earnings and parent-level economics can diverge. Physician alignment may support retention while minority interests affect the value accruing to shareholders.

  10. 10
    03 · SITUATION MAP

    Growth and Margin Sort the Set into Four Operating Groups, and Valuation Varies Across Them

    This page sorts companies into four operating groups using the sector's median multiple and median growth rate as cut lines.

    We cut the rated set on EV/EBITDA against the 8.7x sector median and on revenue growth against the covered median to produce four operating groups. This is an observation of where companies sit today, not a recommendation to buy or sell any of them. The pattern sets up the growth-versus-profitability view on the next page.

    Everything on this page

    03 · SITUATION MAP Growth and Margin Sort the Set into Four Operating Groups, and Valuation Varies Across Them Cut on EV / EBITDA vs the sector median (8.7x) (rows) and revenue growth vs the covered median (6%) (columns) · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Outpatient and Specialty Care Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Higher Valuation, Higher Growth Above-median multiple · above-median revenue growth 4 names Concentra Group Holdings Parent, Inc. (CON) · Option Care Health, Inc. (OPCH) · U.S. Physical Therapy, Inc. (USPH) · +1 more Four names sit above the middle of the peer set on both valuation and revenue growth. Their position pairs current operating momentum with stronger market confidence. Higher Valuation, Lower Growth Above-median multiple · below-median revenue growth 2 names HCA Healthcare, Inc. (HCA) · Surgery Partners, Inc. (SGRY) Two names carry an above-middle valuation despite below-middle revenue growth. Their position suggests that profitability, durability or business-model attributes are also present in market pricing. Lower Valuation, Higher Growth Below-median multiple · above-median revenue growth 2 names Astrana Health, Inc. (ASTH) · Alignment Healthcare, Inc. (ALHC) Two names deliver above-middle revenue growth while remaining below the middle on valuation. The gap frames questions around margin conversion, revenue quality and confidence in the growth path. Lower Valuation, Lower Growth Below-median multiple · below-median revenue growth 4 names Community Health Systems, Inc. (CYH) · Ardent Health Inc. (ARDT) · National Vision Holdings, Inc. (EYE) · +1 more Four names sit below the middle on both measures. Their operating questions center on growth recovery, cost structure, payer mix and capital allocation.

  11. 11
    03 · GROWTH VS PROFITABILITY

    The Top of the Range Sits with the Names Clearing Both Operating Bars

    This page plots revenue growth against EBITDA margin and shows the median multiple for each quadrant.

    Plotting growth against margin, with cuts at the covered medians, shows the top of the valuation range sitting with the names that clear both bars, at 14.7x, against 6.4x for the names clearing neither. This is consistent with the market distinguishing profitable expansion from volume growth on its own. We treat this quadrant as the clearest evidence in the deck for why operating quality, not just growth, sits with the premium.

    Everything on this page

    03 · GROWTH VS PROFITABILITY The Top of the Range Sits with the Names Clearing Both Operating Bars Revenue growth (CY2027E, x-axis) vs EBITDA margin (CY2027E, y-axis) · 12 companies with both estimates · cuts at the covered medians (6% growth, 11% margin) · median EV/EBITDA per quadrant · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Quadrant cuts are the covered set's medians. Quadrant medians on names with a meaningful EV/EBITDA (balanced n=2; margin-only n=4; growth-only n=4; neither n=2). ALHC plotted at the chart edge. Outpatient and Specialty Care Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 0% 5% 10% 15% 20% 5% 10% 15% 20% MARGIN ONLY median 8.5x BALANCED median 14.7x NEITHER median 6.4x GROWTH ONLY median 8.7x SGRY CYH JYNT HCA ARDT EYE CON OPCH USPH INNV ASTH ALHC x: revenue growth (CY2027E) · y: EBITDA margin (CY2027E) HOW TO READ THIS Among the 12 names with a forward EV / EBITDA estimate, two clear both bars at 14.7x, four clear only the margin bar at 8.5x, four clear only the growth bar at 8.7x and two clear neither at 6.4x. Concentra Group Holdings Parent, Inc. (CON) and U.S. Physical Therapy, Inc. (USPH) occupy the balanced group. The middle groups show that growth or profitability alone can support value without creating the same position. Rule of 40 (revenue growth + EBITDA margin ≥ 40%): 0 of 12 names clear it.

  12. 12
    03 · THE AGENDA

    Operating Priorities Depend on Whether Growth or Profitability Is the Constraint

    This page frames the operating questions an owner or acquirer should resolve based on whether growth or profitability is the binding constraint.

    Where growth is the constraint, the question is what's limiting capacity or referral volume. Where profitability lags, the question turns to pricing, case mix and labor deployment. These are observations grounded in the cohort data, framed as questions to resolve rather than as recommendations.

    Everything on this page

    03 · THE AGENDA Operating Priorities Depend on Whether Growth or Profitability Is the Constraint NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Outpatient and Specialty Care Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12 Protect Profitable Growth Test whether expansion preserves mature-site economics, clinician productivity and payer mix while new capacity ramps. What changes the answer: Same-store performance remains resilient as de novo sites and acquired locations mature. Convert Growth into Earnings Examine pricing, case mix, labor deployment and site maturity where revenue growth has yet to translate into stronger profitability. What changes the answer: Incremental revenue begins to carry a more durable contribution after clinician and site costs. Restart the Growth Engine Assess whether block time, referral funnels, provider capacity or contracted rates are limiting otherwise profitable operations. What changes the answer: Available capacity and clinician coverage can support additional cases or visits. Rework the Operating Model Review market density, service mix, fixed costs and build-versus-buy choices where growth and profitability both trail the peer set. What changes the answer: A focused market or service-line plan offers a credible route to better unit economics.

  13. 13
    SECTION 04

    04

    This divider introduces the section on precedent transactions across care delivery, specialty networks and occupational health.

    Buyers have paid across care delivery, specialty networks and occupational health. The transaction record ahead shows strategic and financial buyers underwriting distinct routes to scale.

    Everything on this page

    SECTION 04 04 PRECEDENT TRANSACTIONS Buyers Have Paid Across Care Delivery, Specialty Networks and Occupational Health The transaction record shows strategic and financial buyers underwriting distinct routes to scale. 04 of 06 Outpatient and Specialty Care Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13

  14. 14
    04 · DEAL CASE STUDIES

    Precedent Transactions Spread Across Several Routes to Care Delivery Scale

    This page walks through a set of disclosed-terms transactions as case studies, with the complete list in the appendix.

    We highlight three transactions with disclosed terms as case studies, drawn from a broader set of precedent deals with disclosed terms. These multiples are calculated on LTM financials at announcement, so we don't compare them directly to the CY2027E public multiples used elsewhere in this deck. Each case illustrates a different route to care delivery scale, which is why we read them individually rather than as a single average.

    Everything on this page

    04 · DEAL CASE STUDIES Precedent Transactions Spread Across Several Routes to Care Delivery Scale 3 of 19 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 69 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate filings collapsed); figures are shown as recorded in the filing. 37 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Outpatient and Specialty Care Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14 Feb-2023 $10.2B CVS Health Corporation CVS Health Corporation’s agreement to acquire Oak Street Health, Inc. brought care delivery into a… EV / LTM revenue 4.7x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The combination suggests that CVS Health Corporation saw strategic value in adding a care delivery organization. It aligns with payer and healthcare buyers seeking closer links to patient capacity. HOW THE TARGET WAS VALUED The announced value was $10.2B at 4.7x EV / Revenue. That revenue benchmark is more relevant to a model whose earnings profile is still developing than a direct comparison with the sector’s lead EV / EBITDA lens. Jan-2025 $6.2B Bain Capital Private Equity, LP Bain Capital Private Equity, LP’s agreement to acquire Surgery Partners, Inc. put a scaled surgical… EV / LTM revenue 2.0x EV / LTM EBITDA 12.3x WHY THE DEAL HAPPENED The transaction suggests sponsor conviction in the cash earnings and expansion potential of a surgical facility platform. The strategic fit centers on a scaled network where site of service, case mix and physician alignment matter. HOW THE TARGET WAS VALUED The announced value was $6.2B at 12.3x EV / EBITDA and 2.0x EV / Revenue. The earnings measure benchmarks directly against the peer set’s lead lens, subject to transaction timing and adjustment differences. Jan-2025 $265M Concentra Group Holdings Concentra Group Holdings added Nova Medical Centers to deepen its occupational care network. EV / LTM revenue n/a EV / LTM EBITDA 9.4x WHY THE DEAL HAPPENED The combination suggests a network-density strategy within occupational care. Greater local coverage can sit alongside employer relationships, clinician capacity and referral access. HOW THE TARGET WAS VALUED The completed transaction carried a value of $265M at 9.4x EV / EBITDA. That measure benchmarks directly against the peer set’s lead lens, with transaction structure and earnings adjustments kept in view.

  15. 15
    SECTION 05

    05

    This divider introduces the section on strategic implications for converting growth into durable earnings.

    Value strengthens when growth converts into durable earnings. The operating agenda ahead centers on revenue quality, capacity use, payer mix and repeatable expansion.

    Everything on this page

    SECTION 05 05 STRATEGIC IMPLICATIONS Value Strengthens When Growth Converts into Durable Earnings The operating agenda centers on revenue quality, capacity use, payer mix and repeatable expansion. 05 of 06 Outpatient and Specialty Care Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15

  16. 16
    05 · STRATEGIC IMPLICATIONS

    Durable Earnings Sit with Better Revenue Quality and Capacity Economics

    This page sets out the operating questions for owners, operators and boards implied by the valuation findings.

    For owners, the relevant question is whether growth is same-store or acquired, and whether payer mix supports durable rates. For operators, block time utilization and clinician productivity determine whether demand becomes profitable growth. For boards, capital allocation should follow the specific constraint at hand rather than a general expansion plan. These are our views drawn from the analysis in this report, not investment recommendations.

    Everything on this page

    05 · STRATEGIC IMPLICATIONS Durable Earnings Sit with Better Revenue Quality and Capacity Economics NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Outpatient and Specialty Care Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16 FOR OWNERS Know Which Economics Support the Company’s Standing The relevant questions are whether growth is same-store or acquired, whether payer mix supports durable rates and whether physician interests leave sufficient earnings at the parent. FOR OPERATORS Turn Capacity into Repeatable Contribution Block time utilization, clinician productivity, credentialing and de novo ramp determine whether demand becomes profitable case and visit growth. FOR BOARDS Match Capital Allocation to the Constraint Build-versus-buy choices should reflect whether the binding issue is local density, clinician supply, service mix, payer positioning or site maturity.

  17. 17
    SECTION 06

    06

    This divider introduces the appendix covering the full comparable universe, methodology and sources.

    The appendix carries the full universe, the valuation basis and the source for every figure in this report. It's here so any number in the body can be traced back to where it came from.

    Everything on this page

    SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Outpatient and Specialty Care Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17

  18. 18
    06 · PUBLIC COMPARABLES (1 OF 1)

    Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier

    This page lists the rated companies grouped by valuation tier against the 8.7x sector median.

    We list every rated company against the 8.7x sector median, alongside one additional name with no eligible EV/EBITDA multiple. Tickers link to the underlying source so any figure here can be verified directly. This table is the full basis for every valuation claim made earlier in the deck.

    Everything on this page

    06 · PUBLIC COMPARABLES (1 OF 1) Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/EBITDA above the sector median (8.7x); amber marks below · 12 rated companies; 1 not rated (no eligible EV/EBITDA) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 12 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Outpatient and Specialty Care Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Company Ticker Segment EV EV/EBITDA (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥11.2x · median 13.3x · 3 companies U.S. Physical Therapy, Inc. USPH Hospital-affiliated outpatient and surgical facility… $2.0B 16.8x 8% 13% 20 Surgery Partners, Inc. SGRY Hospital-affiliated outpatient and surgical facility… $7.5B 13.3x -1% 17% 16 Concentra Group Holdings Parent, Inc. CON Hospital-affiliated outpatient and surgical facility… $6.6B 12.6x 6% 21% 27 CORE — 7.8x–11.2x · median 8.7x · 6 companies Innovage Holding Corp. INNV Hospital-affiliated outpatient and surgical facility… $1.2B 10.7x 8% 10% 18 HCA Healthcare, Inc. HCA Hospital-affiliated outpatient and surgical facility… $148B 9.1x 4% 20% 24 Option Care Health, Inc. OPCH Hospital-affiliated outpatient and surgical facility… $4.7B 9.0x 7% 8% 15 Astrana Health, Inc. ASTH Hospital-affiliated outpatient and surgical facility… $2.6B 8.3x 10% 7% 17 National Vision Holdings, Inc. EYE Retail-format optometry and vision clinics $1.9B 8.1x 5% 11% 16 Community Health Systems, Inc. CYH Hospital-affiliated outpatient and surgical facility… $10.7B 7.9x 1% 12% 13 DISCOUNT — <7.8x · median 5.9x · 3 companies The Joint Corp. JYNT Hospital-affiliated outpatient and surgical facility… $97M 7.4x 3% 21% 24 Alignment Healthcare, Inc. ALHC Adjacent: risk-bearing payer-provider organizations $1.2B 5.9x 25% 3% 28 Ardent Health Inc. ARDT Hospital-affiliated outpatient and surgical facility… $2.4B 4.6x 4% 8% 12

  19. 19
    06 · PRECEDENT TRANSACTIONS (1 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This page lists disclosed-terms precedent transactions, newest first, out of a larger recorded set.

    This table lists the transactions with disclosed terms, newest first, drawn from a larger set of recorded deals. Multiples shown are calculated on LTM financials at announcement, and deal values link to the underlying filing. We keep the full recorded set, including transactions without disclosed terms, in the companion workbook.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 19 transactions with disclosed terms in this tier (56 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 69 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate filings collapsed); figures are shown as recorded in the filing. 37 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 19 transactions shown; the rest are in the companion workbook. Outpatient and Specialty Care Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Jan-2025 Bain Capital Private Equity, LP → Surgery Partners, Inc. $6.2B 2.0x 12.3x Bain Capital Private Equity, LP agreed to acquire Surgery Partners, Inc. The transaction suggests continued financial-buyer interest in scaled surgical facility networks. Jan-2025 Concentra Group Holdings → Nova Medical Centers $265M n/a 9.4x Concentra Group Holdings completed its acquisition of Nova Medical Centers. The combination suggests value in expanding an occupational care network. Nov-2024 Cencora, Inc. → Retina Consultants of America $4.6B n/a n/a Cencora, Inc. completed its acquisition of Retina Consultants of America. The transaction links a healthcare strategic with a specialty care network. Jul-2024 Concentra Group Holdings Parent, Inc. → U.S. Occmed Holdings, LLC d/b/a Nova Medical Centers n/a n/a 9.4x Concentra Group Holdings Parent, Inc. completed its acquisition of U.S. Occmed Holdings, LLC d/b/a Nova Medical Centers. The fit suggests an emphasis on network density and care delivery scale. Feb-2023 CVS Health Corporation → Oak Street Health, Inc. $10.2B 4.7x n/a CVS Health Corporation agreed to acquire Oak Street Health, Inc. The combination suggests interest in bringing care delivery capacity closer to a broader healthcare model. Nov-2022 Walgreens Boots Alliance, Inc. → Summit Health-CityMD n/a 3.1x n/a Walgreens Boots Alliance, Inc. agreed to acquire Summit Health-CityMD. The transaction pairs a healthcare strategic with a broad care delivery network. Jul-2021 1Life Healthcare Inc. → Iora Health, Inc. n/a 9.5x n/a 1Life Healthcare Inc. agreed to acquire Iora Health, Inc. The transaction suggests a strategic fit between two care delivery organizations. Jun-2021 DFP Healthcare Acquisitions Corp. → TOI Parent, Inc. $842M n/a n/a DFP Healthcare Acquisitions Corp. agreed to acquire TOI Parent, Inc. The transaction connected specialty care delivery with a public-market route. Feb-2021 Fortress Value Acquisition Corp. II → ATI Physical Therapy, Inc. n/a n/a 18.2x Fortress Value Acquisition Corp. II agreed to acquire ATI Physical Therapy, Inc. The transaction suggests interest in a scaled outpatient therapy network.

  20. 20
    06 · PRECEDENT TRANSACTIONS (2 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This page continues the list of disclosed-terms precedent transactions, newest first.

    This continues the transaction list from the previous page, still ordered newest first. The same LTM-at-announcement basis applies, and we don't compare these multiples directly to the CY2027E public basis used elsewhere. The full recorded set remains available in the companion workbook.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 19 transactions with disclosed terms in this tier (56 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 69 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate filings collapsed); figures are shown as recorded in the filing. 37 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 19 transactions shown; the rest are in the companion workbook. Outpatient and Specialty Care Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 20 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Dec-2020 USPI Holding Company, Inc. → portfolio of up to 45 ambulatory surgical centers $1.1B n/a n/a Nov-2018 TPG Capital → Greencross n/a n/a 10.0x Value shown as recorded in the filing; deal value unit unresolved. Oct-2017 Select Medical Holdings Corporation → U.S. HealthWorks, Inc. n/a n/a 12.0x Jan-2017 Mars, Incorporated → VCA Inc. n/a n/a 18.3x Feb-2016 OMERS → Forefront Dermatology n/a n/a 15.0x Value shown as recorded in the filing; deal value unit unresolved. Jan-2016 Select Medical Holdings Corporation → Physiotherapy Associates Holdings, Inc. n/a n/a 12.5x Jun-2014 Surgery Partners, Inc. → Symbion Inc. n/a n/a 10.3x May-2012 DaVita Inc. → Health Care Partners Medical Group, P.C. n/a 1.3x n/a Feb-2011 Kindred Healthcare, Inc. → RehabCare Group, Inc. n/a n/a 7.7x

  21. 21
    06 · METHODOLOGY

    Sources, Assumptions and Data Quality

    This page explains the report's sources, assumptions and data-quality treatment.

    Every figure in this report links back to the record it was taken from, and where no link exists, the appendix names the source and the basis for the figure. We disclose what was excluded and why, so the report's scope stays transparent. This is the reference page for anyone checking a specific number.

    Everything on this page

    06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Outpatient and Specialty Care Services Coverage | September 2026 | Confidential | Not investment advice 21 VALUATION BASIS Primary valuation basis: EV / EBITDA on CY2027E consensus (12 of 13 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Outpatient and Specialty Care Services and it clears the coverage gate with 12 of 13 companies (92%). EV / Revenue, P / E are carried as a cross-check. The set earns: 12 of the 13 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. DATA QUALITY & EXCLUSIONS 14 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 609 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (608) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.

  22. 22

    The Premium Sits with Durable Growth, Profitability and Credible Care Economics.

    The closing page restates that the valuation premium sits with durable growth, profitability and credible care economics.

    The premium in this sector sits with durable growth, profitability and credible care economics, not with growth or scale alone. The companion tables carry the full universe and source index for any figure a client wants to trace.

    Everything on this page

    The Premium Sits with Durable Growth, Profitability and Credible Care Economics. NeuraCap AI — Outpatient and Specialty Care Services Coverage September 2026 · Prepared by NeuraCap AI · Confidential Outpatient and Specialty Care Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 22

Sources and methodology

This report covers Outpatient and Specialty Care Services (Health Care › Health Care Equipment and Services › Outpatient and Specialty Care Services) with market data and consensus estimates as of September 28, 2026. The company universe is the 13 listed companies whose core business is Outpatient and Specialty Care Services according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Alignment Healthcare, Inc. (ALHC), Ardent Health Inc. (ARDT), Astrana Health, Inc. (ASTH), Concentra Group Holdings Parent, Inc. (CON), Community Health Systems, Inc. (CYH), National Vision Holdings, Inc. (EYE), HCA Healthcare, Inc. (HCA), Innovage Holding Corp. (INNV), The Joint Corp. (JYNT), Option Care Health, Inc. (OPCH), PROCEPT BioRobotics Corporation (PRCT), Surgery Partners, Inc. (SGRY), U.S. Physical Therapy, Inc. (USPH). The market map groups them by business vertical — Hospital-affiliated outpatient and surgical facility networks: 10 companies (HCA, CYH, SGRY, CON, OPCH, ASTH, ARDT, USPH, INNV, JYNT); Adjacent models: 3 companies (EYE, ALHC, PRCT). 12 of the 13 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

Scope and company universe

This report covers Outpatient and Specialty Care Services (Health Care › Health Care Equipment and Services › Outpatient and Specialty Care Services) with market data and consensus estimates as of September 28, 2026. The company universe is the 13 listed companies whose core business is Outpatient and Specialty Care Services according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Alignment Healthcare, Inc. (ALHC), Ardent Health Inc. (ARDT), Astrana Health, Inc. (ASTH), Concentra Group Holdings Parent, Inc. (CON), Community Health Systems, Inc. (CYH), National Vision Holdings, Inc. (EYE), HCA Healthcare, Inc. (HCA), Innovage Holding Corp. (INNV), The Joint Corp. (JYNT), Option Care Health, Inc. (OPCH), PROCEPT BioRobotics Corporation (PRCT), Surgery Partners, Inc. (SGRY), U.S. Physical Therapy, Inc. (USPH). The market map groups them by business vertical — Hospital-affiliated outpatient and surgical facility networks: 10 companies (HCA, CYH, SGRY, CON, OPCH, ASTH, ARDT, USPH, INNV, JYNT); Adjacent models: 3 companies (EYE, ALHC, PRCT). 12 of the 13 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

What was excluded and why

14 records failed a validation gate and never feed a statistic in this report (14 excluded from aggregate). Each exclusion, with its reason: ALHC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ALHC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CYH — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CYH — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · INNV — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · JYNT — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · PRCT — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · PRCT — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · PRCT — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · PRCT — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · PRCT — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · PRCT — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · PRCT — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · SGRY — Non-positive EPS; P/E is n/m (effect: excluded from aggregate)

Primary valuation basis and how it was chosen

Primary valuation basis: EV / EBITDA on CY2027E consensus (12 of 13 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Outpatient and Specialty Care Services and it clears the coverage gate with 12 of 13 companies (92%). EV / Revenue, P / E are carried as a cross-check. The set earns: 12 of the 13 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 12 of 13 companies; EV / rEVenue: 13 of 13 companies; P/E: 11 of 13 companies. 1 company shows a non-meaningful EV / EBITDA denominator and is excluded from that statistic. 2 companies show a non-meaningful P / E denominator and are excluded from that statistic.

How the multiples and statistics are computed

Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥11.2x, Core 7.8x–11.2x, Discount <7.8x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 8.7x = median(ev_ebitda CY2027E) (12 rated companies) · 13.3x = median(ev_ebitda CY2027E) within Premium tier (n=3) · 8.7x = median(ev_ebitda CY2027E) within Core tier (n=6) · 5.9x = median(ev_ebitda CY2027E) within Discount tier (n=3) · 9.9x = median(ev_ebitda CY2027E) | growth ≥ 6% (n=6) · 8.0x = median(ev_ebitda CY2027E) | growth < 6% (n=6) · 10.9x = median(ev_ebitda CY2027E) | EBITDA margin ≥ 11% (n=6) · 8.2x = median(ev_ebitda CY2027E) | EBITDA margin < 11% (n=6) · 17% = median Rule of 40 score (revenue growth + EBITDA margin) (n=12) · 14.7x = median(ev_ebitda CY2027E) within balanced quadrant (n=2) · 8.5x = median(ev_ebitda CY2027E) within marginOnly quadrant (n=4) · 8.7x = median(ev_ebitda CY2027E) within growthOnly quadrant (n=4) · 6.4x = median(ev_ebitda CY2027E) within neither quadrant (n=2)

Precedent transactions: what is in the record and why

The precedent record holds the M&A transactions in Outpatient and Specialty Care Services recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 56 transactions were recorded for this industry; 19 are shown. 37 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 29 × deal value unit unresolved; 32 × no evidence record; 3 × duplicate precedent id; 1 × duplicate filings collapsed; 2 × divestiture roles reassigned; 2 × financial target ev not meaningful. Case studies lead with the 3 richest stories — disclosed value, a readable multiple, newest first.

Sources

Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 613 source documents stand behind this report; by publisher domain: sec.gov, home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.

Interpretation and important notice

Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.

Sources linked in the report

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Outpatient and Specialty Care Services?

Company valuation reports run the same method against a single business — public or private.